This document summarises the evidence base on the use of medicines in people with or at increased risk of acute kidney injury . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants , including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
The key therapeutic topic biosimilar medicines has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .
This document summarises the evidence base on wound care products . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
The key therapeutic topic non-steroidal anti-inflammatory drugs has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .
This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
The key therapeutic topic laxatives has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .
The key therapeutic topic first-choice antidepressant use in adults with depression or generalised anxiety disorder has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .
The key therapeutic topic renin-angiotensin system drugs: dual therapy has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .
The key therapeutic topic minocycline has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
ES33 Product overview The content of this evidence summary was up to date in February 2021. New evidence may have been
Summary of the evidence on beclometasone, formoterol and glycopyrronium (Trimbow) for chronic obstructive pulmonary disease (COPD) to inform local NHS planning
Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer
Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection
ES12 Key points The content of this evidence summary
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
Summary of the evidence on antimicrobial prescribing: delafloxacin
Summary of the evidence on antimicrobial prescribing: cefiderocol
Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders
ES34 Product overview The content of this evidence summary was up to date in January 2021. New evidence may have been
Summary of the evidence on dimethyl sulfoxide bladder instillation for treating interstitial cystitis to inform local NHS planning and decision-making
Summary of the evidence on oral ketamine for treating chronic pain to inform local NHS planning and decision-making
Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making
Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making
Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis...
Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making
Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making
Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making
ES23 . Key messages The content of this evidence review was up to date on 24 March 2020. New evidence may have been published since
ES26 . Key messages The content of this evidence review was up to date on 13 May 2020. New evidence may have been published since
ES27 . Key messages The content of this evidence review was up to date on 4 June 2020. New evidence has been published since then
ES24 . Key messages The content of this evidence review was up to date on 1 April 2020. New evidence may have been published since
ES25 . Key messages The content of this evidence review was up to date on 20 April 2020. New evidence may have been published since
Summary of the evidence on ceftazidime/avibactam for complicated intra-abdominal and UTI infections and hospital-acquired pneumonia
Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making
Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making
Summary of the evidence on the levonorgestrel intrauterine delivery system (long-acting reversible contraception) to inform local NHS planning...
Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making
Summary of the evidence on sucroferric oxyhydroxide for treating hyperphosphataemia in adults with chronic kidney disease (CKD) on dialysis..
Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making
Summary of the evidence on beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) for treating asthma in adults..
Summary of the evidence on olodaterol for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making
Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making
Summary of the evidence on fluticasone/formoterol (Flutiform) combination inhaler for treating asthma to inform local NHS planning and decision-making